JPWO2025005306A1 - - Google Patents
Info
- Publication number
- JPWO2025005306A1 JPWO2025005306A1 JP2025509007A JP2025509007A JPWO2025005306A1 JP WO2025005306 A1 JPWO2025005306 A1 JP WO2025005306A1 JP 2025509007 A JP2025509007 A JP 2025509007A JP 2025509007 A JP2025509007 A JP 2025509007A JP WO2025005306 A1 JPWO2025005306 A1 JP WO2025005306A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025064259A JP2025108531A (ja) | 2023-10-05 | 2025-04-09 | ウラシル誘導体を含有する医薬組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023173420 | 2023-10-05 | ||
| JP2023173420 | 2023-10-05 | ||
| JP2024096866 | 2024-06-14 | ||
| JP2024096866 | 2024-06-14 | ||
| PCT/JP2024/035560 WO2025005306A1 (ja) | 2023-10-05 | 2024-10-04 | ウラシル誘導体を含有する医薬組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025064259A Division JP2025108531A (ja) | 2023-10-05 | 2025-04-09 | ウラシル誘導体を含有する医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2025005306A1 true JPWO2025005306A1 (https=) | 2025-01-02 |
| JP7674711B1 JP7674711B1 (ja) | 2025-05-12 |
| JPWO2025005306A5 JPWO2025005306A5 (https=) | 2025-06-04 |
Family
ID=93938355
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025509007A Active JP7674711B1 (ja) | 2023-10-05 | 2024-10-04 | ウラシル誘導体を含有する医薬組成物 |
| JP2025064259A Pending JP2025108531A (ja) | 2023-10-05 | 2025-04-09 | ウラシル誘導体を含有する医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025064259A Pending JP2025108531A (ja) | 2023-10-05 | 2025-04-09 | ウラシル誘導体を含有する医薬組成物 |
Country Status (4)
| Country | Link |
|---|---|
| JP (2) | JP7674711B1 (https=) |
| AU (1) | AU2024307335A1 (https=) |
| TW (1) | TW202523309A (https=) |
| WO (1) | WO2025005306A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12021552872A1 (en) * | 2020-04-05 | 2022-03-21 | Pfizer | Compounds and methods for the treatment of covid-19 |
| US11351149B2 (en) * | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| LT4122926T (lt) * | 2021-04-14 | 2025-07-25 | Shionogi & Co., Ltd. | Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija |
| JP7624093B2 (ja) * | 2022-04-08 | 2025-01-29 | 塩野義製薬株式会社 | ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物 |
-
2024
- 2024-10-04 AU AU2024307335A patent/AU2024307335A1/en active Pending
- 2024-10-04 WO PCT/JP2024/035560 patent/WO2025005306A1/ja active Pending
- 2024-10-04 JP JP2025509007A patent/JP7674711B1/ja active Active
- 2024-10-04 TW TW113137842A patent/TW202523309A/zh unknown
-
2025
- 2025-04-09 JP JP2025064259A patent/JP2025108531A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7674711B1 (ja) | 2025-05-12 |
| TW202523309A (zh) | 2025-06-16 |
| WO2025005306A1 (ja) | 2025-01-02 |
| AU2024307335A1 (en) | 2026-04-16 |
| JP2025108531A (ja) | 2025-07-23 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250217 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250217 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20250217 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250318 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250411 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20250403 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7674711 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |